Treatment Resistant Depression Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight | Navitor Pharmaceuticals, Supernus Pharmaceuti, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome The

DelveInsight's "Treatment Resistant Depression Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of historical and forecasted epidemiology as well as Treatment-Resistant Depression therapeutics market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Treatment Resistant Depression Market Share @ Treatment Resistant Depression Market Outlook- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Treatment Resistant Depression Market Report
• In March 2025, Janssen-Cilag Ltd, announced a study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) in participants who have completed 32 weeks of esketamine nasal spray treatment in Study 54135419TRD3013 (NCT04338321).
• In March 2025, Janssen Research & Development, LLC announced a study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 milligram (mg) and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with treatment resistant depression (TRD), as assessed by the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from Day 1 (prerandomization) to the end of the 4 week double-blind treatment phase (Day 28).
• In March 2025, COMPASS Pathways announced a study will last up to 16 weeks including a three- to ten-week Screening Period and six-week follow-up from investigational product (IP) administration. This is a phase III, international, multi-centre, randomised, parallel group, fixed repeat dose, double-blind, controlled study. The study population will include participants aged ≥18 years with TRD.
• In March 2025, atai Therapeutics Inc. announced a phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major Depressive disorder (TRD) and will characterize the onset and durability of antidepressant effects of VLS-01-BU versus placebo. The total diagnosed prevalent cases of Treatment-Resistant Depression in the 7MM were approximately 6,409,000 cases in 2022 and are projected to increase during the forecast period (2023-2032).
• The United States contributed to the largest number of diagnosed prevalent cases of Treatment-Resistant Depression (~71%) in the 7MM in 2022. Whereas EU4 and the UK, and Japan accounted for around 25% and 4% of the total diagnosed prevalent cases of Treatment-Resistant Depression in the 7MM, respectively, in 2022.
• Among the EU4 countries, Germany accounted for the highest number of total diagnosed prevalent cases of Treatment-Resistant Depression, whereas Italy accounted for the lowest number of cases in 2022.
• DelveInsight estimates that around 512,000 cases and 1,117,000 cases of Treatment-Resistant Depression were observed in males and females, respectively, in EU4 and the UK in 2022. The cases are projected to increase during the forecast period.
• In 2022, the maximum number of cases of Treatment-Resistant Depression was found in 50-60 years, and the least number of cases were found in 18-29 years in the US.
• The leading Treatment Resistant Depression Companies such as Navitor Pharmaceuticals, Supernus Pharmaceuti, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others.
• Promising Treatment Resistant Depression Pipeline Therapies such as NV5138, MIJ821, REL-1017, BPL-003, COMP360 (Psilocybin), AXS-05, FALKIERI (esketamine DPI), and others.

Stay ahead in the Treatment Resistant Depression Therapeutics Market with DelveInsight's Strategic Report @ Treatment Resistant Depression Market Outlook- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Treatment Resistant Depression Epidemiology Segmentation in the 7MM
• Total Treatment Resistant Depression Prevalent Cases
• Treatment Resistant Depression Age-specific Cases
• Treatment Resistant Depression Gender-specific Cases
• Treatment Resistant Depression Treated Cases

Download the report to understand which factors are driving Treatment Resistant Depression Epidemiology Trends @ Treatment Resistant Depression Prevalence- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Treatment Resistant Depression Market Insights
The five main Treatment Resistant Depression strategies used to overcome a partial response or lack of response to antidepressant therapy are optimization, switching, combination, augmentation, and somatic therapies. Because there is no standard treatment approach, mental health experts offer the aforesaid strategies based on the re-evaluation of patients with treatment-resistant depression. The patient with depression not responding to antidepressant monotherapy requires a highly individualized treatment plan, and accordingly, some people will respond to a specific treatment, while others do not.

Treatment Resistant Depression Treatment Landscape
The Treatment Resistant Depression treatment response of patients suffering from TRD varies from patient to patient. According to various researches, 10-30% of patients suffering from TRD who take antidepressants experience a poor response with residual symptoms and are required to try a variety of treatment alternatives. On the other hand, recently some developmental initiatives have been taken towards the management of treatment-resistant depression that can be seen by the interest shown in this area by some key players. Therefore, with some interesting therapies that are being investigated in the pipeline, the condition of the market for this disease should evolve. This would further encourage reimbursement of insurance, adoption by doctors, compliance with patients, and, eventually, the genesis of a broad, untapped sector.

To learn more about Treatment Resistant Depression treatment guidelines, visit @ Treatment Resistant Depression Treatment Market Landscape- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Treatment Resistant Depression Emerging Therapies
• Non-Pharmacologic (VNS, ECT, TNS etc.)
• SYMBYAX (Eli Lilly)
• Antidepressants
• SPRAVATO (Johnson & Johnson)
• NV-5138 (Navitor Pharmaceuticals/ Supernus Pharmaceuticals)
• MIJ821 (Novartis)

Treatment Resistant Depression Drugs Uptake
• NV-5138 is a first-in-class, orally active small molecule that selectively activates mTORC1 in the brain. The sestrin-binding leucine mimetic, developed by Navitor's scientists, is based on observations that sestrin is the protein component of the mTORC1 pathway that senses availability of amino acids like leucine. NV-5138 offers the potential for rapid-acting antidepressant benefits without the psychotomimetic side effects and abuse potential observed with other rapid acting agents. It is being developed in collaboration with the Supernus Pharmaceuticals for the treatment of TRD. The drug is currently being evaluated for its safety and efficacy in its Phase II trials.
• DB104, or liafensine, is a potential first-in-class drug targeting TRD. Denovo discovered a novel genetic biomarker for DB104 efficacy using its unique machine learning approach with whole genome sequencing. It is a triple reuptake inhibitor targeting transporters for dopamine, serotonin, and norepinephrine. Recently it announced dosing of the first patient in its biomarker-guided global Phase IIb clinical trial (ENLIGHTEN) to assess the safety and efficacy of DB104 (liafensine) in patients with TRD.

Treatment-Resistant Depression Market Dynamics
The treatment-resistant depression market dynamics are anticipated to change in the coming years. We have a robust pipeline of treatments currently in development, featuring innovative Mechanisms of Action (MoA), enhanced safety profiles, and improved tolerability, aimed at addressing Treatment-Resistant Depression (TRD). This includes compounds such as MIJ821 and Psilocybin, among others. The recent approval of esketamine nasal spray for TRD patients is a significant milestone, signifying a positive outlook for the treatment-resistant depression market. Esketamine promises to be a transformative therapy due to its unique mechanism of action and ease of administration.

Learn more about the FDA-approved drugs for Treatment Resistant Depression @ Drugs for Treatment Resistant Depression Treatment- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Treatment Resistant Depression Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Treatment Resistant Depression Companies- Navitor Pharmaceuticals, Supernus Pharmaceuti, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and several others.
• Treatment Resistant Depression Pipeline Therapies- NV5138, MIJ821, REL-1017, BPL-003, COMP360 (Psilocybin), AXS-05, FALKIERI (esketamine DPI), and others.
• Treatment Resistant Depression Market Dynamics: Treatment Resistant Depression Market Drivers and Barriers

Discover more about Treatment Resistant Depression Drugs in development @ Treatment Resistant Depression Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Report Introduction
2. Treatment Resistant Depression Market Overview at a Glance
3. Executive Summary of Treatment-Resistant Depression (TRD)
4. Key Events
5. Treatment Resistant Depression Disease Background and Overview
6. Treatment Resistant Depression Treatment
7. Treatment Resistant Depression Methodology
8. Treatment Resistant Depression Epidemiology and Patient Population
9. Patient Journey
10. Treatment Resistant Depression Marketed Drugs
11. Treatment Resistant Depression Emerging Drugs
12. Treatment-Resistant Depression (TRD): Seven Major Market Analysis
13. Treatment Resistant Depression KOL Views
14. Treatment Resistant Depression SWOT Analysis
15. Treatment Resistant Depression Unmet Needs
16. Reimbursement and Market Access
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

Joint reconstruction devices market- https://www.delveinsight.com/report-store/joint-reconstruction-devices-market
NK Cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Positive airway pressure device market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
Congenital heart defect market- https://www.delveinsight.com/report-store/congenital-heart-defect-devices-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Diabetic wound market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Transcatheter treatment market- https://www.delveinsight.com/report-store/transcatheter-treatment-market
Chronic neuropathic pain market- https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
CAR-T Pipeline- https://www.delveinsight.com/report-store/car-t-pipeline-insight
Surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Intraocular lens market- https://www.delveinsight.com/report-store/intraocular-lens-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Vascular access devices market- https://www.delveinsight.com/report-store/vascular-access-device-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.